Lexicon's SONATA-HCM heads to Q1 2027 with no HCM drug yet SGLT-class approved
Sotagliflozin, already approved for heart failure, is being tested as the first SGLT1/SGLT2 inhibitor in hypertrophic cardiomyopathy, with topline data due in Q1 2027.
Executive Summary
- Lexicon's pivotal HCM trial for sotagliflozin is heading toward a defined data window, testing whether an already-approved cardiometabolic drug can extend into a disease area with no comparable mechanism on record.
- The sponsor has held its readout timing steady across repeated disclosures, and the trial's registry footprint shows no material instability, which shifts the open question from execution risk to what the data show.
- No other industry trial anywhere in development is testing an SGLT-class mechanism in hypertrophic cardiomyopathy, so the readout carries no direct precedent to benchmark against.
- A result that clears a clinically meaningful symptom-score threshold would open a path toward a label expansion for a drug already marketed for heart failure, rather than a de novo approval decision.
The trial
SONATA-HCM (NCT06481891) is a randomized, placebo-controlled Phase 3 study enrolling 500 adults with obstructive or non-obstructive hypertrophic cardiomyopathy, a disease marked by thickened heart muscle that can obstruct blood flow and limit exercise capacity. The primary endpoint is the change from baseline to week 26 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS), a patient-reported measure of symptoms and physical limitation. Secondary endpoints track the KCCQ Total Symptom Score and the share of patients gaining at least one New York Heart Association functional class. The trial started recruiting on September 24, 2024, and its listed primary completion date is July 1, 2026. NCT06481891A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The guidance trail
Lexicon has repeated the same Q1 2027 topline timing across three consecutive disclosures: at the J.P. Morgan Healthcare Conference on January 12, 2026, again on March 5, 2026, and once more on May 7, 2026. At the January conference, chief executive Mike Exton said the company is "executing on multiple fronts to deliver breakthrough therapies for patients," and the same release stated the study was targeting enrollment completion in mid-2026 with topline data anticipated in Q1 2027. The trial's own registry record shows no change in primary completion date and one eligibility-criteria amendment since the study was added in mid-2024, a pattern the registry-churn proxy classifies as stable. Lexicon+1Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan ...Jan 12, 2026A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891
The mechanism gap
Sotagliflozin already carries FDA approval as Inpefa, an oral SGLT1/SGLT2 inhibitor for heart failure, so SONATA-HCM tests whether that established mechanism extends into a different cardiac disease rather than testing a new molecule. No other industry trial at any phase is studying an SGLT1 or SGLT2 inhibitor in hypertrophic cardiomyopathy, leaving sotagliflozin as the only asset in this target-indication pairing to reach Phase 3. The nearest active competitors in HCM itself work through different mechanisms: Cytokinetics' aficamten and Bristol-Myers Squibb's mavacamten are both cardiac myosin inhibitors, and Tenaya Therapeutics' TN-201 is a gene therapy targeting the MYBPC3 mutation, none of which share sotagliflozin's SGLT-class biology.
Regulatory path
Lexicon has said that if SONATA-HCM reads out positively, it plans to submit a supplemental New Drug Application seeking a broad HCM label, a conditional regulatory plan tied directly to the trial's outcome. That plan means the readout functions as the gating event for a label-expansion filing rather than a first-in-human approval decision, consistent with the drug's existing approval in heart failure. NCT06481891A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.